Lake Street Advisors Group LLC Purchases 406 Shares of Sanofi (NASDAQ:SNY)

Lake Street Advisors Group LLC raised its position in Sanofi (NASDAQ:SNY) by 6.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 7,121 shares of the company’s stock after buying an additional 406 shares during the period. Lake Street Advisors Group LLC’s holdings in Sanofi were worth $343,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Pinnacle West Asset Management Inc. raised its stake in shares of Sanofi by 12.2% during the fourth quarter. Pinnacle West Asset Management Inc. now owns 4,600 shares of the company’s stock valued at $222,000 after acquiring an additional 500 shares during the last quarter. IFP Advisors Inc raised its position in Sanofi by 17.2% during the 4th quarter. IFP Advisors Inc now owns 2,132 shares of the company’s stock worth $103,000 after purchasing an additional 313 shares during the last quarter. Atlantic Family Wealth LLC acquired a new position in Sanofi during the 4th quarter worth about $262,000. Oxbow Advisors LLC raised its position in shares of Sanofi by 4.8% during the fourth quarter. Oxbow Advisors LLC now owns 104,749 shares of the company’s stock worth $5,052,000 after acquiring an additional 4,790 shares during the last quarter. Finally, Bank of Stockton lifted its position in shares of Sanofi by 6.0% in the 4th quarter. Bank of Stockton now owns 6,251 shares of the company’s stock worth $301,000 after purchasing an additional 352 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNY. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Stock Performance

Shares of Sanofi stock opened at $54.14 on Friday. The business has a 50-day simple moving average of $51.51 and a 200 day simple moving average of $52.59. Sanofi has a one year low of $45.22 and a one year high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a market capitalization of $137.40 billion, a price-to-earnings ratio of 21.74, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.